The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.25
Bid: 15.00
Ask: 15.50
Change: -2.75 (-15.28%)
Spread: 0.50 (3.333%)
Open: 15.50
High: 16.50
Low: 15.25
Prev. Close: 18.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Shield closer to Canada approval; Angle plans raise

Thu, 14th Jul 2022 21:44

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Shield Therapeutics PLC - Newcastle, England-based commercial-stage pharmaceutical company - Its Accrufer-Feraccru iron deficiency treatment gets new drug submission approval from Health Canada. "Health Canada are expected to complete their regulatory review in mid-2023 and a successful outcome will allow KYE to market Accrufer in Canada. Shield will be responsible for all manufacturing and supply to the Canadian market," it adds. Company nets GBP250,000 milestone payment for approval and eligible for an additional GBP600,000 in milestone payments upon the achievement of specified calendar net sales targets.

----------

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Subsidiary Akili Interactive Labs Inc's Systemic Lupus Erythematosus treatment, AKL-T01, sees significant improvement in motor speed and executive functions in study. The study results were published in the medical journal Lupus, it notes. Akili Chief Medical Officer Anil Jina says: "The results of this study in patients with SLE are consistent with the cognitive improvements seen in other studies after using our digital therapeutic. We are excited to see this continued validation of our technology platform as we advance our pipeline to deliver clinically meaningful cognitive and quality-of-life improvements across patient populations."

----------

Audioboom Group PLC - London-based podcast producer - Renews partnerships with "key" podcasts including Dark History, Murder Mystery & Makeup and No Such Thing As A Fish. Also plans to expand "creator network" through new commercial agreements with two podcasts, Fair Game with Leah Remini and The Roman Atwood Podcast.

----------

Angle PLC - Surrey, England-based medical diagnostics company - Proposes placing equal to 10% of existing issued share capital through placing and subscription. Says net proceeds will be used to help its commercialisation plans for its Parsortix system. Number of shares to be placed, and the price, will be determined after the bookbuild closes. Hopes to raise about GBP20 million.

----------

Greatland Gold PLC - mine developer and explorer in Western Australia - Renegotiates obligations for consideration due under the original 2016 acquisition of the Havieron project. Initial deal sees payment of AUD25,000 cash and issue of 65.5 million shares and further 145.5 million shares conditional upon Greatland's ownership interest in Havieron reducing to 25% on a decision to mine at Havieron. Says Five Diggers, who is receiving the shares, now agrees to take 4.5% reduction in shares, now totalling 139.0 million and equals GBP14.5 million saving, and agrees to 2-year restriction on dealing.

Shaun Day, managing director of Greatland Gold, says: "This is an excellent outcome, simultaneously removing the uncertainty of this long-standing share issue, reducing shareholder dilution by decreasing the number of shares being issued and introduces a two-year restriction on dealing with the shares."

----------

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Sees "successful results" of clinical study into the influence of its ArtemiC Support on patients with post-acute Covid Syndrome, also known as long Covid. "ArtemiC Support, has demonstrated the ability of the supplement to improve the symptoms of long Covid," it says.

----------

Panther Metals PLC - mineral exploration in Canada - "Delighted" with "stunning" drilling results from Burtville East gold project and Eight Foot Well prospect in Western Australia. Notes result finds 1 metre at 79.90 grammes per tonne gold from 27 metres and 1 metre at 478.00 grammes per tonne from 28 metres, both coming from hole BVE006. Chief Executive Darren Hazelwood says the results reinforce the case for further exploration at Burtville East.

----------

Premier African Minerals Ltd - British Virgin Islands-based minerals and metals project developer - Sees "impressive" results from Zulu lithium and tantalum project. "The work to date has provided the level of confidence we needed internally to support the pilot plant concept as recently announced. In fact, what we are now understanding about the Zulu deposit is entirely complementary to the use of sensor-based ore sorting and in time is likely to result in a most efficient and effective process," Chief Executive George Roach says.

----------

Capital Ltd - mining services company - Wholly-owned subsidiary MSALABS expands partnership with Chrysos Corp. Tie in will see MSALABS deploy 21 Chrysos PhotonAssay units across its project by 2025. Notes revenue guidance for MSALABS in 2022 remains about USD30 million. Following the rollout of the further 15 units across 2023 and 2024, in conjunction with the expansion of the existing geochemistry business, MSALABS anticipates generating revenues in excess of USD80 million per annum.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
29 Aug 2019 09:12

Angle initiates main phase of ovarian cancer clinical study

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the main phase of its 200-patient ovarian cancer clinical verification study has been initiated and the first patient has been enrolled.

Read more
22 Jul 2019 12:53

Angle's Parsortix Used For Analysis Of Circulating Tumor Cells

(Alliance News) - Angle PLC on Monday said one of its leading customers, the Disseminated Cancer Cell Network, has published new results of work done to develop a "robust, reliable and for of

Read more
25 Jun 2019 08:16

Angle looks to strengthen balance sheet and extend runway via placement

(Sharecast News) - Liquid biopsy company Angle will look to raise up £18m at 61.5p per ordinary share through finnCap and WG Partners in order to strengthen its balance sheet and enable the development of key products.

Read more
21 Jun 2019 15:26

Angle upbeat on recent cancer research results

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the University Medical Centre Hamburg-Eppendorf (UKE) cancer centre has published results of work demonstrating that its 'Parsortix' system can be used as a liquid biopsy to investigate programmed death-ligand 1 (PD-L1) status in non small cell lung cancer (NSCLC) patients.

Read more
21 Jun 2019 12:56

Angle's Parsortix Successfully Investigates Immunotherapy Target

(Alliance News) - Angle PLC on Friday said its Parsortix system has been successfully used as a liquid biopsy to investigate an immunotherapy target in lung cancer.Shares in Angle were up a

Read more
5 Jun 2019 13:04

Angle's Parsortix And HyCEAD Ziplex Systems Identify Cancer In Study

LONDON (Alliance News) - Angle PLC on Wednesday announced positive results from a study evaluating the ability of its Parsortix and HyCEAD Ziplex platforms to test for ovarian cancer.The to

Read more
31 May 2019 09:53

Angle reveals positive results from latest Parsortix study

(Sharecast News) - Liquid biopsy company Angle announced positive results from its 'Parsortix' FDA clinical study for metastatic breast cancer on Friday.

Read more
26 Apr 2019 12:48

Angle's Parsortix system used in more groundbreaking research

(Sharecast News) - Liquid biopsy company Angle announced on Friday that its 'Parsortix' system has been utilised in further groundbreaking new cancer research, demonstrating the role of myeloid-derived suppressor cells (MDSCs) as part of large circulating tumor cell (CTC) clusters, which are 50x more likely to generate metastasis than single CTCs, for the first time.

Read more
26 Apr 2019 12:29

Angle's Parsortix System Used In Further "Groundbreaking" Research

LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said its Parsortix system has been used in "groundbreaking" cancer research.The research showed the first the time

Read more
18 Apr 2019 11:35

US Cancer Centre Uses Angle's Parsortix System For Assessments

LONDON (Alliance News) - Angle PLC on Thursday said its ParsortixTM system was used by the University of Texas MD Anderson Cancer Center to develop a new technique for assessing the metastatic of

Read more
12 Apr 2019 15:25

Angle's Parsortix to be used in new Greece study

(Sharecast News) - Liquid biopsy company Angle announced on Friday that a leading customer has established a multi-centre study to investigate biomarkers on circulating tumor cells (CTCs), using its 'Parsortix' system, which could give advance warning of relapse in non small cell lung cancer (NSCLC).

Read more
12 Apr 2019 11:59

University Of Athens Cancer Study To Use Angle's Parsortix System

LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said a "leading" customer has set up a multi-centre study using its Parsortix system.The study is being carried out

Read more
7 Mar 2019 13:09

Angle Enrols All 400 Patients In US Breast Cancer Study For Parsortix

LONDON (Alliance News) - Angle PLC on Thursday said it has completed enrolment for a US study of its Parsortix biopsy technology in metastatic breast cancer.All of the 400 subjects required

Read more
7 Mar 2019 09:35

Angle completes enrolment in Parsortix breast cancer study

(Sharecast News) - Liquid biopsy company Angle announced on Thursday that enrolment for its 'Parsortix' FDA clinical study for metastatic breast cancer was now complete.

Read more
28 Feb 2019 13:30

Angle Enrolls First Patients In Ovarian Cancer Study

LONDON (Alliance News) - Angle PLC on Thursday said it has enrolled the first patients in an ovarian cancer verification study, after receiving ethics approval.The study will be divided a a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.